24th December 2019
Unaudited Half Year Results
Nuformix (LSE: NFX), the pharmaceutical development Group using cocrystal technology…
News
25th November 2019
Update and Placing Announcement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
28th October 2019
Share Listing Anouncement
Following the receipt of Notice of Conversion of Loan Note…
25th October 2019
Statement re. Share Price Movement
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
10th September 2019
NFX Results of AGM 2019
The Annual General Meeting of Nuformix plc
10th September 2019
Resignation of Kirk Siderman-Wolter from the Board of Directors
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
9th September 2019
Ebers Tech Strategic Cannabinoid Collaboration Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
6th September 2019
Appointment of Dr Muhunthan Thillai to Nuformix Scientific Advisory Board
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
4th September 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
18th July 2019
Final Results for year ended 31 March 2019
The Board of Nuformix plc, (LSE:NFX) is pleased to announce…
7th June 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
6th June 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
30th May 2019
Positive Results for NXP001 Clinical Trial
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology…
24th May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
24th May 2019
Notice of Loan Conversion
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the…
22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
22nd May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
15th May 2019
Nuformix Achieves Second NXP001 Development Milestone
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
8th May 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
9th April 2019
Nuformix Enters Strategic Cannabinoid Agreement
Cambridge, UK, 9 April 2019: Nuformix (LSE: NFX), the pharmaceutical…
5th April 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
22nd March 2019
Nuformix Commences NXP001 Clinical Trial
Cambridge, UK, 22 March 2019: Nuformix (LSE: NFX), the pharmaceutical…
27th February 2019
Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology…
20th February 2019
Notification Major Share Interests
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
20th December 2018
Nuformix Announces Unaudited Half Year Results for the Period Ending 30 September 2018
Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal…
3rd December 2018
Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
27th November 2018
Nuformix Expands Licensing Agreement with Newsummit Biopharma for cancer supportive care product
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
28th September 2018
Director/PDMR Shareholding
The Company was notified on 28 September 2018 that Kirk…
28th September 2018
Additional New NXP002 Patent Filing
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
19th September 2018
Result of Annual General Meeting
The Annual General Meeting of Nuformix plc was held on…
14th September 2018
NXP001 Pre-Clinical Milestone Achieved
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
28th August 2018
Renewal of Loan Notes
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
16th August 2018
2018 Annual Financial Report and Notice of Annual General Meeting
The Company announces that the following documents were posted to…
15th August 2018
Nuformix PLC – Annual General Meeting – Proxy Form
Nuformix PLC – Annual General Meeting – Proxy Form…
26th July 2018
Final Results for year ended 31 March 2018
The Board of Nuformix plc, (LSE:NFX) is pleased to announce…
4th July 2018
CEO Interview – Dr Daniel Gooding : Nuformix
2nd July 2018
Operational Update
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
26th June 2018
Collaboration with St George Street Capital
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
11th May 2018
Nuformix appoints Dr Chris Blackwell as Non-executive Director
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
24th April 2018
Notification Major Interests Shares
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
2nd March 2018
NFX Update re Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
27th February 2018
TR-1: Standard form for notification of major holdings
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
31st January 2018
Positive Results from NXP002 Pilot Study in Lung and Liver Fibrosis
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
15th December 2017
Cocrystal Agreement for NXP001 with Newsummit Biopharma & £2.5m Payment plus Double Digit Royalty on Sales
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
14th December 2017
NFX Advisory Panel
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
6th December 2017
NFX Broker Appt Warrants
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
1st December 2017
Appointment of Broker
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
19th October 2017
Nuformix signs agreement with Quotient Clinical to commence a pilot bioequivalence study for NXP001
Nuformix, the pharmaceutical development company using cocrystal technology to unlock…
18th October 2017
NFX on Vox Markets
Since shares commenced their first days trading under…
17th October 2017
‘Takeover’s healthy side effect’ – Completion of Nuformix’s acquisition by Levrett plc in The Times
The news of the completion of Nuformix’s acquisition…
16th October 2017
Shakespeare Martineau’s Keith Spedding speaks on Levrett plc’s completed acquisition of Nuformix
Having worked on the original IPO of Levrett,…
16th October 2017
Nuformix CEO, Dan Gooding on Vox Markets – Elevator Pitch
Nuformix CEO, Dan Gooding, provides a first summary…
16th October 2017
‘£12m take-over for Cambridge firm speeding up drug discovery’ – Nuformix RTO featured in the Cambridge News
The news of the completion of Nuformix’s acquisition…
16th October 2017
Nuformix CEO, Dan Gooding, interviewed by Vox Markets’ Justin Waite
As Nuformix shares commence their first days…
16th October 2017
‘Levrett snaps up Cambridge Pharma Company’ – Nuformix RTO featured on Insider Media
The news of the completion of Nuformix’s acquisition…
16th October 2017
Notice of Admission to Trading on The Official List and to Trading on the London Stock Exchange’s Market for Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
16th October 2017
Notice Of Cancellation Of Admission To Trading On The Official List And To Trading On The London Stock Exchange’s Market For Regulated Securities
Following a Reverse Takeover on the London Stock Exchange’s market…
13th October 2017
The Company announces that today the name of the Company has been changed from Levrett plc to Nuformix plc.
Levrett, a Company formed to acquire a target company with…